The Enterprise Value as of December 2025 (TTM) for Apimeds Pharmaceuticals US, Inc (APUS) is 20.19M

According to Apimeds Pharmaceuticals US, Inc’s latest financial reports and current stock price. The company's current Enterprise Value is 20.19M. This represents a change of -8.19% compared to the average of 21.99M of the last 4 quarters.

Apimeds Pharmaceuticals US, Inc (APUS) Historical Enterprise Value (quarterly & annually)

How has APUS Enterprise Value performed in the past?

The mean historical Enterprise Value of Apimeds Pharmaceuticals US, Inc over the last ten years is 25.69M. The current 20.19M Enterprise Value has changed 7.76% with respect to the historical average. Over the past ten years (40 quarters), APUS's Enterprise Value was at its highest in in the March 2025 quarter at 26.08M. The Enterprise Value was at its lowest in in the March 2023 quarter at 0.

Apimeds Pharmaceuticals US, Inc (APUS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Apimeds Pharmaceuticals US, Inc Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Apimeds Pharmaceuticals US, Inc (APUS) Average Enterprise Value

How has APUS Enterprise Value performed in the past?

The current Enterprise Value of Apimeds Pharmaceuticals US, Inc (APUS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Apimeds Pharmaceuticals US, Inc (APUS) Enterprise Value vs. Peers

How is APUS’s Enterprise Value compared to its peers?

Apimeds Pharmaceuticals US, Inc’s Enterprise Value is less than Talphera, Inc. (25.56M), less than MIRA Pharmaceuticals, Inc. (61.23M), greater than SCYNEXIS, Inc. (19.44M), less than Milestone Scientific Inc. (27.15M), less than IGC Pharma, Inc. (25.07M), less than Precision Optics Corporation, Inc. (34.39M), greater than Q32 Bio Inc. (6.85M), greater than AN2 Therapeutics, Inc. (10.96M), less than NextCure, Inc. (33.89M), less than Myomo, Inc. (37.35M),

Build a custom stock screener for Apimeds Pharmaceuticals US, Inc (APUS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Apimeds Pharmaceuticals US, Inc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Apimeds Pharmaceuticals US, Inc (APUS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Apimeds Pharmaceuticals US, Inc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.